OSTX

OSTX

OS Therapies Incorporated Common Stock

$1.840+-0.000 (-0.000%)

Reaalajas hind

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$1.840

Kõrge

$1.840

Madal

$1.840

Maht

0.08M

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Seotud uudised

PR Newswire

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology...

Vaata rohkem
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
Analyst Upgrades

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

D. Boral Capital analyst Jason Kolbert maintains OS Therapies with a Buy and maintains $20 price target.

Vaata rohkem
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
BusinessWire

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

If awarded, OST-HER2 would become the first listeria investigational medicinal product to be awarded the RMAT designation RMAT designation reduces BLA application review time and permits augmented interactions with

Vaata rohkem
OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma